Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.
Raymond Wadlow, MD
Advertisement
Articles by Raymond Wadlow, MD
Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.
Advertisement
Latest Updated Articles
Data Suggest Potential for Immunotherapy in HCCPublished: January 25th 2019 | Updated:
- Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC
Published: February 4th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
